GlycoErase™ PPP1R3B Knockout Glycoengineered Cell (CAT#: GLJF-0825-JF97)

Description	GlycoErase™ PPP1R3B knockout glycoengineered cell eliminates a PP1 glycogen-targeting subunit expressed in liver and skeletal muscle that regulates glycogen synthesis. Variants are linked to type 2 diabetes and MODY. This model supports studies of glycogen metabolism and diabetes.
Product Type	KO Cell Lines
Cell Line	As requested by the client.

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	PPP1R3B
Full Name	Protein Phosphatase 1 Regulatory Subunit 3B
Alternative Name	GL; PTG; PPP1R4
Location	8p23.1
Gene ID	79660
Summary	This gene encodes the catalytic subunit of the serine/theonine phosphatase, protein phosphatase-1. The encoded protein is expressed in liver and skeletal muscle tissue and may be involved in regulating glycogen synthesis in these tissues. This gene may be a involved in type 2 diabetes and maturity-onset diabetes of the young. Alternate splicing results in multiple transcript variants that encode the same protein.